ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00332306
Recruitment Status : Unknown
Verified January 2009 by Tuberculosis Research Centre, India.
Recruitment status was:  Active, not recruiting
First Posted : June 1, 2006
Last Update Posted : October 8, 2009
Sponsor:
Collaborators:
National AIDS Control Organisation
Indian Council of Medical Research
Information provided by:
Tuberculosis Research Centre, India

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : June 2009
  Estimated Study Completion Date : December 2011
Publications:
J. M. Molina, S Perusat, F Ferchal, C Rancinan, F raffi, W Rozenbaum, D Sereni, P Morlat, G Chene and the Montana Study Group: Once-Daily Combination Therapy with Emtricitabine, Didanosine and Efavirenz in Treatment-Naïve HIV-Infected Adults: 64-week Follow-Up of the ANRS 091 Trial.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):